PEDIATRIX MEDICAL GROUP INC (MD) Stock Fundamental Analysis
USA - NYSE:MD - US58502B1061 - Common Stock
21.93 USD
+0.11 (+0.5%)
21.93 USD
0 (0%)
We assign a fundamental rating of 5 out of 10 to MD. MD was compared to 100 industry peers in the Health Care Providers & Services industry. Both the profitability and the financial health of MD get a neutral evaluation. Nothing too spectacular is happening here. A decent growth rate in combination with a cheap valuation! Better keep an eye on MD. This makes MD very considerable for value investing!
1. Profitability
1.1 Basic Checks
MD had positive earnings in the past year.
MD had a positive operating cash flow in the past year.
In multiple years MD reported negative net income over the last 5 years.
MD had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 5.23%, MD is in the better half of the industry, outperforming 79.00% of the companies in the same industry.
MD has a Return On Equity of 13.18%. This is in the better half of the industry: MD outperforms 78.00% of its industry peers.
MD's Return On Invested Capital of 9.55% is fine compared to the rest of the industry. MD outperforms 80.00% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for MD is in line with the industry average of 9.42%.
The last Return On Invested Capital (9.55%) for MD is above the 3 year average (7.83%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.23% | ||
| ROE | 13.18% | ||
| ROIC | 9.55% |
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
1.3 Margins
Looking at the Profit Margin, with a value of 5.66%, MD is in the better half of the industry, outperforming 79.00% of the companies in the same industry.
The Operating Margin of MD (10.97%) is better than 79.00% of its industry peers.
MD's Operating Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.97% | ||
| PM (TTM) | 5.66% | ||
| GM | N/A |
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
MD has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for MD has been increased compared to 1 year ago.
The number of shares outstanding for MD has been increased compared to 5 years ago.
Compared to 1 year ago, MD has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.19 indicates that MD is not a great score, but indicates only limited risk for bankruptcy at the moment.
MD has a Altman-Z score (2.19) which is comparable to the rest of the industry.
MD has a debt to FCF ratio of 2.68. This is a good value and a sign of high solvency as MD would need 2.68 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 2.68, MD is doing good in the industry, outperforming 79.00% of the companies in the same industry.
MD has a Debt/Equity ratio of 0.70. This is a neutral value indicating MD is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.70, MD is in line with its industry, outperforming 54.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.7 | ||
| Debt/FCF | 2.68 | ||
| Altman-Z | 2.19 |
ROIC/WACC1.04
WACC9.15%
2.3 Liquidity
MD has a Current Ratio of 1.80. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of MD (1.80) is better than 71.00% of its industry peers.
MD has a Quick Ratio of 1.80. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
MD has a Quick ratio of 1.80. This is in the better half of the industry: MD outperforms 72.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.8 |
3. Growth
3.1 Past
MD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.92%, which is quite impressive.
Measured over the past years, MD shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -15.01% on average per year.
MD shows a small growth in Revenue. In the last year, the Revenue has grown by 0.92%.
MD shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.49% yearly.
EPS 1Y (TTM)56.92%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%52.27%
Revenue 1Y (TTM)0.92%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-3.58%
3.2 Future
Based on estimates for the next years, MD will show a small growth in Earnings Per Share. The EPS will grow by 3.76% on average per year.
The Revenue is expected to grow by 2.34% on average over the next years.
EPS Next Y23.94%
EPS Next 2Y12.52%
EPS Next 3Y9.51%
EPS Next 5Y3.76%
Revenue Next Year-5.59%
Revenue Next 2Y-1.52%
Revenue Next 3Y0.03%
Revenue Next 5Y2.34%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 10.75, the valuation of MD can be described as reasonable.
89.00% of the companies in the same industry are more expensive than MD, based on the Price/Earnings ratio.
MD is valuated cheaply when we compare the Price/Earnings ratio to 25.67, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 11.63, which indicates a very decent valuation of MD.
Compared to the rest of the industry, the Price/Forward Earnings ratio of MD indicates a rather cheap valuation: MD is cheaper than 85.00% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 31.86. MD is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.75 | ||
| Fwd PE | 11.63 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MD is valued a bit cheaper than 79.00% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MD indicates a rather cheap valuation: MD is cheaper than 88.00% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.41 | ||
| EV/EBITDA | 8.6 |
4.3 Compensation for Growth
MD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.45
PEG (5Y)N/A
EPS Next 2Y12.52%
EPS Next 3Y9.51%
5. Dividend
5.1 Amount
MD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
21.93
+0.11 (+0.5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners97.31%
Inst Owner Change-1.43%
Ins Owners1.9%
Ins Owner Change8.02%
Market Cap1.91B
Revenue(TTM)2.01B
Net Income(TTM)109.92M
Analysts78.67
Price Target17.09 (-22.07%)
Short Float %3.22%
Short Ratio3.71
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)26.94%
Min EPS beat(2)21.14%
Max EPS beat(2)32.73%
EPS beat(4)4
Avg EPS beat(4)26.19%
Min EPS beat(4)15.9%
Max EPS beat(4)34.96%
EPS beat(8)6
Avg EPS beat(8)10.2%
EPS beat(12)6
Avg EPS beat(12)3.22%
EPS beat(16)9
Avg EPS beat(16)4.71%
Revenue beat(2)0
Avg Revenue beat(2)-1.7%
Min Revenue beat(2)-1.97%
Max Revenue beat(2)-1.44%
Revenue beat(4)1
Avg Revenue beat(4)-0.9%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)0.31%
Revenue beat(8)1
Avg Revenue beat(8)-2.7%
Revenue beat(12)1
Avg Revenue beat(12)-2.84%
Revenue beat(16)2
Avg Revenue beat(16)-2.48%
PT rev (1m)1.01%
PT rev (3m)-2.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.33%
EPS NY rev (1m)0%
EPS NY rev (3m)7.69%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.76%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.62%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.75 | ||
| Fwd PE | 11.63 | ||
| P/S | 0.98 | ||
| P/FCF | 8.41 | ||
| P/OCF | 7.81 | ||
| P/B | 2.29 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.6 |
EPS(TTM)2.04
EY9.3%
EPS(NY)1.89
Fwd EY8.6%
FCF(TTM)2.61
FCFY11.89%
OCF(TTM)2.81
OCFY12.81%
SpS22.29
BVpS9.57
TBVpS-4.8
PEG (NY)0.45
PEG (5Y)N/A
Graham Number20.96
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.23% | ||
| ROE | 13.18% | ||
| ROCE | 12.09% | ||
| ROIC | 9.55% | ||
| ROICexc | 11.91% | ||
| ROICexgc | 104.6% | ||
| OM | 10.97% | ||
| PM (TTM) | 5.66% | ||
| GM | N/A | ||
| FCFM | 11.7% |
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
ROICexc(3y)8.94%
ROICexc(5y)8.89%
ROICexgc(3y)78.23%
ROICexgc(5y)75.12%
ROCE(3y)9.91%
ROCE(5y)9.03%
ROICexgc growth 3Y26.95%
ROICexgc growth 5Y24.1%
ROICexc growth 3Y3.64%
ROICexc growth 5Y14.51%
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.92
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.7 | ||
| Debt/FCF | 2.68 | ||
| Debt/EBITDA | 2.47 | ||
| Cap/Depr | 73.88% | ||
| Cap/Sales | 0.9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 103.31% | ||
| Profit Quality | 206.51% | ||
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.8 | ||
| Altman-Z | 2.19 |
F-Score7
WACC9.15%
ROIC/WACC1.04
Cap/Depr(3y)81.28%
Cap/Depr(5y)89.11%
Cap/Sales(3y)1.42%
Cap/Sales(5y)1.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.92%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%52.27%
EPS Next Y23.94%
EPS Next 2Y12.52%
EPS Next 3Y9.51%
EPS Next 5Y3.76%
Revenue 1Y (TTM)0.92%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-3.58%
Revenue Next Year-5.59%
Revenue Next 2Y-1.52%
Revenue Next 3Y0.03%
Revenue Next 5Y2.34%
EBIT growth 1Y39.69%
EBIT growth 3Y-5.51%
EBIT growth 5Y-4.62%
EBIT Next Year49.88%
EBIT Next 3Y15.85%
EBIT Next 5YN/A
FCF growth 1Y63.28%
FCF growth 3Y60.68%
FCF growth 5Y-11.42%
OCF growth 1Y43.72%
OCF growth 3Y39.11%
OCF growth 5Y-10.4%
PEDIATRIX MEDICAL GROUP INC / MD FAQ
What is the ChartMill fundamental rating of PEDIATRIX MEDICAL GROUP INC (MD) stock?
ChartMill assigns a fundamental rating of 5 / 10 to MD.
What is the valuation status of PEDIATRIX MEDICAL GROUP INC (MD) stock?
ChartMill assigns a valuation rating of 8 / 10 to PEDIATRIX MEDICAL GROUP INC (MD). This can be considered as Undervalued.
How profitable is PEDIATRIX MEDICAL GROUP INC (MD) stock?
PEDIATRIX MEDICAL GROUP INC (MD) has a profitability rating of 5 / 10.
How financially healthy is PEDIATRIX MEDICAL GROUP INC?
The financial health rating of PEDIATRIX MEDICAL GROUP INC (MD) is 5 / 10.
What is the expected EPS growth for PEDIATRIX MEDICAL GROUP INC (MD) stock?
The Earnings per Share (EPS) of PEDIATRIX MEDICAL GROUP INC (MD) is expected to grow by 23.94% in the next year.